305 related articles for article (PubMed ID: 27659856)
1. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
2. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
3. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
4. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
5. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
6. Results from Cardiovascular Outcome Trials in Diabetes.
Muñoz Torres M; Muñoz Garach A
Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
[No Abstract] [Full Text] [Related]
7. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
8. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Mudher Mikhael E
J Diabetes Res; 2016; 2016():6962574. PubMed ID: 27642611
[TBL] [Abstract][Full Text] [Related]
9. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Takayanagi R; Uchida T; Kimura K; Yamada Y
Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
[TBL] [Abstract][Full Text] [Related]
11. New oral hypoglycaemics fail to show cardiovascular benefits.
Cohen D
BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
[No Abstract] [Full Text] [Related]
12. Diabetes: Cardiovascular safety of 'gliptin' therapy.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
[No Abstract] [Full Text] [Related]
13. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Greenhill C
Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
[No Abstract] [Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Davis TM
Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
[No Abstract] [Full Text] [Related]
15. Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Kuritzky L
Am J Med Sci; 2010 Aug; 340(2):133-43. PubMed ID: 20571352
[TBL] [Abstract][Full Text] [Related]
16. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Tibaldi JM
Adv Ther; 2014 Mar; 31(3):289-317. PubMed ID: 24535623
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
[TBL] [Abstract][Full Text] [Related]
18. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
[TBL] [Abstract][Full Text] [Related]
19. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
Gallwitz B; Nitschmann S
Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
[No Abstract] [Full Text] [Related]
20. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Derosa G; Maffioli P
N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
[No Abstract] [Full Text] [Related]
[Next] [New Search]